JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With Locally Advanced Head & Neck Squamous Cell Carcinoma
- Carcinoma, Squamous Cell
At a glance
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Enrolment target
- 500
- Started
- 10 December 2021
- Main results due (estimated)
- 30 June 2028
- Study ends (estimated)
- 30 June 2028
- Allocation
- Randomized
- Design
- Parallel
- Purpose
- Treatment
- Masking
- None
- Sites
- 196 · 8 in India
- First posted
- 19 May 2021
- Registry updated
- 3 November 2026
Can you take part?
- Aged 60 years and over.
- Open to any sex.
- You need the condition being studied. Healthy volunteers are not accepted.
Age groups: adult, older adult.
These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Age greater than or equal to (\>=) 60 years old * Biopsy-confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or supraglottic larynx and a candidate for definitive radiation therapy with or without cetuximab * Clinical stage T3-4 NX or T2 N2-3 disease according to the 8th edition of AJCC * One primary tumor lesion amendable for intratumoral injection * Ineligible to receive platinum-based chemotherapy with radiation (at least one of the following): 1. Estimated creatinine clearance \>= 30 and less than (\<) 50 milliliters/minute (mL/min) (per Cockcroft-Gault equation), 2. Grade \>= 2 hearing loss or tinnitus, 3. Grade \>= 2 peripheral neuropathy, 4. New York Heart Association Class 3 5. Aged 70-74 years old with Geriatric 8 (G8) score less than or equal to (\<=) 14 or Aged \>= 75 years old * Eastern cooperative oncology group (ECOG) performance status 0 to 1 * Life expectancy \>= 6 months Exclusion Criteria: * Carcinoma of the nasopharynx, paranasal sinus, salivary gland, or thyroid gland; or non-squamous histology or SCC of unknown primary origin * Clinical stage T1-2 N0, T2 N1, or M1 disease according to the 8th edition of AJCC * Loco-regionally recurrent head \& neck cancer that has been previously treated with surgery, radiation therapy, and/or chemotherapy * Prior or concurrent primary malignancy (including second synchronous head \& neck cancer) within the last 2 years of informed consent and whose natural history has the potential to interfere with the safety and efficacy assessment of the investigational agent * Ongoing or active infection requiring treatment with antimicrobial therapy within 2 weeks of randomization
What this study is about
In the sponsor’s own words, from the registry.
This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve, platinum-ineligible, elderly participants with locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
Keywords: LA-HNSCC · NBTXR3 · hafnium oxide · radioenhancer · Radiotherapy · RT · HNSCC · radiation therapy
What participants receive
- Experimental
Arm A: JNJ-90301900 (NBTXR3)
JNJ-90301900 (NBTXR3), as an intratumoral/intranodal injection, activated by investigator's choice of RT alone or RT in combination with cetuximab. JNJ-90301900 (NBTXR3) is given as a dose of 33% of the Gross Tumor Volume.
Drug: JNJ-90301900 (NBTXR3) · Drug: Cetuximab · Radiation: Radiation Therapy
- Active comparator
Arm B: RT alone or RT in combination with cetuximab
Investigator's choice of RT alone or RT in combination with cetuximab.
Drug: Cetuximab · Radiation: Radiation Therapy
Interventions
JNJ-90301900 (NBTXR3)Drug
Also known as Functionalized hafnium oxide nanoparticles, NBTXR3
Suspension of inert, crystalline hafnium oxide particles, designed to generate oxygen free radicals to destroy cancer cells after activation by ionizing radiation.
CetuximabDrug
Also known as Erbitux
Solution for infusion
Radiation TherapyRadiation
Intensity-modulated radiation therapy (IMRT): 70 Gray in 35 fractions over a 7-week period.
What the study measures
Primary outcomes
Progression-free Survival (PFS) Based on Independent Central Review (ICR)
PFS is defined as time from randomization to local-regional progression (including recurrence), distant progression, or death from any cause, whichever occurs first.
Time frame: 30 months following first randomized participant
Secondary outcomes
Overall Survival (OS)
Time from randomization to death from any cause.
Time frame: 48 months following first randomized participant
Local-regional control
Time to local regional progression: time from randomization to local-regional progression (including recurrence) or death, whichever occurs first.
Time frame: 48 months following first randomized participant
Distant control
Time to distant progression: time from randomization to distant progression or death, whichever occurs first.
Time frame: 48 months following first randomized participant
Quality of Life over time - QLQ H&N35
Change from baseline over time in symptoms, function, and health related QOL using the European organisation for research and treatment of cancer (EORTC) questionnaire-head and neck cancer module (QLQ H\&N35).
Time frame: 48 months following first randomized participant
Quality of Life over time - EQ 5D 5L
Change from baseline over time in symptoms, function, and health related QOL using the 5 level EuroQol 5 dimension (EQ 5D 5L) instrument.
Time frame: 48 months following first randomized participant
Safety across duration of study - AEs
Adverse events (AEs).
Time frame: 48 months following first randomized participant
Objective Response Rate (ORR)
Rate of complete response (CR)+partial response (PR) \[RESIST 1.1\].
Time frame: 48 months following first randomized participant
Duration of Overall Response
Time from CR or PR to progression of disease, unequivocal clinical progression, or death, whichever occurs first.
Time frame: 48 months following first randomized participant
Head and Neck Cancer Specific Event-Free Survival
Time from randomization to loco regional progression (including recurrence), distant progression, or head and neck cancer related death, as per RECIST 1.1, whichever occurs first.
Time frame: 48 months following first randomized participant
Head and Neck Cancer-Specific Survival
Time from randomization to head and neck cancer-related death.
Time frame: 48 months following first randomized participant
Who is running it
- Lead sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Sponsor type
- Industry
- Responsible party
- The sponsor
- Organisation
- Johnson & Johnson Enterprise Innovation Inc.
- Data monitoring committee
- Yes
- US FDA-regulated drug
- Yes
- US FDA-regulated device
- No
- Sponsor's study ID
- NANORAY-312
- Other IDs
- NANORAY-312, 2024-520386-31-00
Johnson & Johnson Enterprise Innovation Inc Clinical trial
Study director
Johnson & Johnson Enterprise Innovation Inc.
Study sites(196)
M S Ramaiah Memorial Hospital
Bangalore, India
Recruiting
Tata Memorial Hospital
Mumbai, India
Recruiting
HealthCare Global HCG Manavata Cancer Centre
Nashik, India
Recruiting
Rajiv Gandhi Cancer Institute and Research Centre
New Delhi, India
Recruiting
HCG cancer center
Vijayawada, India
Recruiting
Apollo Speciality Hospital, Chennai
Chennai, India
Completed
Meenakshi Mission Hospital and Research Center
Madurai, India
Completed
Grant Medical foundation Ruby Hall Clinic
Pune, India
Completed
University of Alabama at Birmingham
Birmingham, Alabama, United States
Recruiting
City of Hope
Duarte, California, United States
Recruiting
University of California at San Diego Moores Cancer Center
La Jolla, California, United States
Recruiting
UCLA Hematology Oncology
Los Angeles, California, United States
Recruiting
University of California San Francisco
San Francisco, California, United States
Recruiting
George Washington University Cancer Center
Washington D.C., District of Columbia, United States
Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
Recruiting
AdventHealth Orlando
Orlando, Florida, United States
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
Recruiting
Emory University Hospital Midtown
Atlanta, Georgia, United States
Recruiting
University of Kentucky Markey Cancer Center
Lexington, Kentucky, United States
Recruiting
Boston Medical Center
Boston, Massachusetts, United States
Recruiting
Richmond University Medical Center
Staten Island, New York, United States
Recruiting
Montefiore Medical Center
The Bronx, New York, United States
Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Recruiting
Atrium Health Levine Cancer Institute
Charlotte, North Carolina, United States
Recruiting
University of Cincinnati
Cincinnati, Ohio, United States
Recruiting
Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
Recruiting
Oregon Health And Science University
Portland, Oregon, United States
Recruiting
University of Pennsylvania Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, United States
Recruiting
University of Virginia
Charlottesville, Virginia, United States
Recruiting
Macon Joan Brock Virginia Health Sciences Eastern Virginia Medical Group at Old Dominion University
Norfolk, Virginia, United States
Recruiting
Medical University Innsbruck
Innsbruck, Austria
Recruiting
Ordensklinikum Linz GmbH Barmherzige Schwestern
Linz, Austria
Recruiting
Medizinische Universitaet Wien
Vienna, Austria
Recruiting
Cliniques Universitaires Saint Luc
Brussels, Belgium
Recruiting
Universitair Ziekenhuis Leuven
Leuven, Belgium
Recruiting
Fundacao Pio XII
Barretos, Brazil
Recruiting
Nucleo de Ensino e Pesquisa do Instituto Mario Penna
Belo Horizonte, Brazil
Recruiting
Instituto Do Cancer Do Ceara
Fortaleza, Brazil
Recruiting
Fundacao Sao Francisco Xavier
Ipatinga, Brazil
Recruiting
Fundacao Doutor Amaral Carvalho
Jaú, Brazil
Recruiting
Showing 40 of 196 sites. 134 recruiting, 62 not recruiting and 0 cancelled; 8 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.
References and data sharing
- Le Tourneau C, Takacsi-Nagy Z, Nuyts S, Thureau S, Liu F, Hoffmann C, Hackman TG, Lesnik M, Debard A, Finzi L, Devisetty K, Vivar OI, Farber LA, Nguyen F, Liem X, Natelauri E, Psyrri A, Burian M, Yu J, Yom SS. Nanoray-312: phase III study of NBTXR3 + radiotherapy +/- cetuximab in elderly, platinum-ineligible locally advanced HNSCC. Future Oncol. 2025 May;21(12):1489-1499. doi: 10.1080/14796694.2025.2496131. Epub 2025 May 5. PMID 40323213
- Participant data shared
- No
Source: ClinicalTrials.gov record NCT04892173, status verified November 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Interested in this study?
Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.